Topics
High-grade gliomas | Treatment | Targeted therapy | Dabrafenib
Home > Publications > Topics > High-grade gliomas > Treatment > Targeted therapy > Dabrafenib
Kawaguchi
Y, Watanabe Y, Miyakita Y, Ohno M, Ogawa C, Takahashi M,
Yanagisawa S, Mukai T, Igaki H, Sugino H, Yoshida A, Narita Y.
Successful
treatment of pediatric patients with high-grade gliomas featuring
leptomeningeal metastases by targeting BRAF V600E mutations with
dabrafenib plus trametinib: two illustrative cases.
Int
Cancer Conf J.
2024 Apr 10;13(3):256-262. doi:
10.1007/s13691-024-00674-6. PMID:
38962052. Case report˰ ˍ
Castelli B, Tellini M, Guidi M, Di Nicola M, Giunti L, Buccoliero
AM, Censullo ML, Iacono A, Desideri I, Genitori L, Sardi I, Fonte
C.
Case report: complete long-lasting
response to multimodal third line treatment with neurosurgical
resection, carmustine wafer implantation and dabrafenib plus
trametinib in a BRAFV600E
mutated high-grade glioma.
Front
Oncol. 2024 May 7;14:1359093. doi:
10.3389/fonc.2024.1359093. PMID:
38774414. Case report. ˍ
Kawaguchi Y, Hana T, Hasegawa H, Murakami C, Higashi M, Hanakita
S.
Rapid response to BRAF/MEK
inhibitor therapy within 2 weeks for high-grade glioma with
leptomeningeal metastasis: illustrative case.
J
Neurosurg Case Lessons. 2025 Jul 7;10(1):CASE25247.
doi:
10.3171/CASE25247. PMID:
40623326. Case report. ˍ